RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study

BACKGROUND: Although Temozolomide is effective against glioblastoma, the prognosis remains dismal and new regimens with synergistic activity are sought for. METHODS: In this phase-I/II trial, pegylated liposomal doxorubicin (Caelyx™, PEG-Dox) and prolonged administration of Temozolomide in addition...

Descripción completa

Detalles Bibliográficos
Autores principales: Beier, Christoph P, Schmid, Christina, Gorlia, Thierry, Kleinletzenberger, Christine, Beier, Dagmar, Grauer, Oliver, Steinbrecher, Andreas, Hirschmann, Birgit, Brawanski, Alexander, Dietmaier, Christopher, Jauch-Worley, Tanja, Kölbl, Oliver, Pietsch, Torsten, Proescholdt, Martin, Rümmele, Petra, Muigg, Armin, Stockhammer, Günther, Hegi, Monika, Bogdahn, Ulrich, Hau, Peter
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749868/
https://www.ncbi.nlm.nih.gov/pubmed/19725960
http://dx.doi.org/10.1186/1471-2407-9-308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749868/
https://www.ncbi.nlm.nih.gov/pubmed/19725960
http://dx.doi.org/10.1186/1471-2407-9-308

Ejemplares similares